Today: 30 June 2026
Nebius Stock Price Today: NBIS Steadies After $4 Billion Notes Sale
19 March 2026
1 min read

Nebius Stock Price Today: NBIS Steadies After $4 Billion Notes Sale

NEW YORK, March 19, 2026, 12:11 PM EDT

Nebius Group, trading on Nasdaq, saw its shares hovering near flat late Thursday morning. The AI infrastructure firm had just priced a larger-than-planned $4 billion convertible notes deal. Shares slipped roughly 0.3% to $118.20, having moved between $114.04 and $121.75 earlier.

This shift puts the spotlight squarely on what it costs Nebius to land those headline AI contracts. The Amsterdam-based firm is selling $2.25 billion in 2031 notes carrying a 1.25% coupon, and $1.75 billion of 2033 notes at 2.625%. Convertible notes like these can morph into equity down the line, a structure that typically signals dilution risk to investors. Nebius is targeting about $3.96 billion in net proceeds for upgrades—think new data centers, AI cloud buildout, and more GPUs. Conversion kicks in at about $183.22 and $180.31 a share, pricing comfortably above where the stock settled on Tuesday.

Timing here is crucial. Earlier this week, Nebius inked a deal to deliver $12 billion in AI computing power to Meta by 2027, with another $15 billion possible over five years. Nvidia, for its part, disclosed last week it’s grabbing an 8.3% stake for $2 billion. Nebius, much like U.S. rival CoreWeave, is among the “neocloud” players: cloud outfits narrowly targeting AI workloads as Meta signals it could pour up to $135 billion into capacity in 2026. Reuters

CEO Arkady Volozh pointed to the Meta deal as a move that could lock in more sizable, multi-year capacity contracts and quicken Nebius’s push on its main AI cloud platform. The company left its 2026 outlook as is.

Tyler Radke at Citi kicked off coverage with a Buy and set a $169 target, TipRanks reported. Radke pointed to Nebius “scaling ahead of peers” and highlighted the company’s early access to next-gen GPUs. He also noted its capital-efficient approach as a possible edge for grabbing share as AI demand ticks up. TipRanks

The upside, though, isn’t without a big caveat. As Barron’s noted, Radke slapped a “High Risk” tag on the stock, citing Nebius’s thin track record, the heavy capital demands tied to building out multi-gigawatt data centers, and its reliance on just a handful of major cloud clients. Barron’s

The pressure’s clear in the latest numbers. Nebius turned in fourth-quarter revenue of $227.7 million back in February, but the net loss ballooned to $249.6 million as GPU and data center costs piled up. Even so, the company stuck with its projection: closing out 2026 with an annualized revenue run rate between $7 billion and $9 billion, and contracted power topping 3 gigawatts by year-end.

Nebius isn’t new to the capital markets. Back in September, fresh off its $17.4 billion AI infrastructure agreement with Microsoft, the company said it planned to pull in $3 billion, combining convertible notes and equity. The hefty fundraising move, announced alongside a massive deal, underscored how AI infrastructure players often see big ticket wins and big capital demands go hand in hand.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • Telix Pharmaceuticals (ASX:TLX) tops Australian growth stocks with large insider holdings
    June 30, 2026, 3:11 AM EDT. Telix Pharmaceuticals (ASX:TLX) is at the front of Australian growth stocks with high insider ownership, seen as a sign of management confidence. The biopharma group, focused on radiopharmaceuticals in cancer imaging and care, pulled in about US$803.8 million in sales, most of that coming from the U.S. The company's market cap stands at A$5.5 billion. Telix's cancer pipeline is broad, and its commercial footing is firm. Its key products, Illuccix and Gozellix, support 2026 revenue targets of US$950-970 million. There's still risk from regulatory and pricing pressure, but insiders remain aligned, and partnerships with United Imaging and Regeneron support the growth story. Also mentioned: Lindian Resources (ASX:LIN), market cap A$1.7 billion, which is pushing ahead on a rare earths project in Malawi. Both names show that shareholder interest tracks with insider backing.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz
Previous Story

Stock Market Today 09.03.2026

Bitcoin Price Slides Below $70,000 After Fed Warning, Oil Spike Rattle Crypto Stocks
Next Story

Bitcoin Price Slides Below $70,000 After Fed Warning, Oil Spike Rattle Crypto Stocks

Go toTop